Literature DB >> 10586077

Utilization of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation.

Y Le1, W Gong, B Li, N M Dunlop, W Shen, S B Su, R D Ye, J M Wang.   

Abstract

Trp-Lys-Tyr-Val-D-Met (WKYMVm) is a synthetic leukocyte-activating peptide postulated to use seven-transmembrane, G protein-coupled receptor(s). In the study to characterize the receptor(s) for WKYMVm, we found that this peptide induced marked chemotaxis and calcium flux in human phagocytes. The signaling induced by WKYMVm in phagocytes was attenuated by high concentrations of the bacterial chemotactic peptide fMLP, suggesting that WKYMVm might use receptor(s) for fMLP. This hypothesis was tested by using cells over expressing genes encoding two seven-transmembrane receptors, formyl peptide receptor (FPR) and formyl peptide receptor-like 1 (FPRL1), which are with high and low affinity for fMLP, respectively. Both FPR- and FPRL1-expressing cells mobilized calcium in response to picomolar concentrations of WKYMVm. While FPRL1-expressing cells migrated to picomolar concentrations of WKYMVm, nanomolar concentrations of the peptide were required to induce migration of FPR-expressing cells. In contrast, fMLP elicited both calcium flux and chemotaxis only in FPR-expressing cells with an efficacy comparable with WKYMVm. Thus, WKYMVm uses both FPR and FPRL1 to stimulate phagocytes with a markedly higher efficacy for FPRL1. Our study suggests that FPR and FPRL1 in phagocytes react to a broad spectrum of agonists and WKYMVm as a remarkably potent agonist provides a valuable tool for studying leukocyte signaling via these receptors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10586077

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  41 in total

1.  Effect of a novel peptide, WKYMVm- and sirolimus-coated stent on re-endothelialization and anti-restenosis.

Authors:  Eun-Jae Jang; In-Ho Bae; Dae Sung Park; So-Youn Lee; Kyung Seob Lim; Jun-Kyu Park; Jae-Won Shim; Doo Sun Sim; Myung Ho Jeong
Journal:  J Mater Sci Mater Med       Date:  2015-10-05       Impact factor: 3.896

2.  Characterization of Quin-C1 for its anti-inflammatory property in a mouse model of bleomycin-induced lung injury.

Authors:  Min He; Ni Cheng; Wei-wei Gao; Meng Zhang; Yue-yun Zhang; Richard D Ye; Ming-wei Wang
Journal:  Acta Pharmacol Sin       Date:  2011-04-18       Impact factor: 6.150

3.  Enzymatic digestion of the milk protein beta-casein releases potent chemotactic peptide(s) for monocytes and macrophages.

Authors:  Haruki Kitazawa; Kumiko Yonezawa; Masanori Tohno; Takeshi Shimosato; Yasushi Kawai; Tadao Saito; Ji Ming Wang
Journal:  Int Immunopharmacol       Date:  2007-05-21       Impact factor: 4.932

Review 4.  Combinatorial peptide libraries: mining for cell-binding peptides.

Authors:  Bethany Powell Gray; Kathlynn C Brown
Journal:  Chem Rev       Date:  2013-12-03       Impact factor: 60.622

5.  Formylpeptide receptor 1 mediates the tumorigenicity of human hepatocellular carcinoma cells.

Authors:  Liang Zhang; Huanyu Wang; Tianshu Yang; Zhifeng Su; Dan Fang; Yafeng Wang; Jiazhu Fang; Xinwei Hou; Yingying Le; Keqiang Chen; Ji Ming Wang; Shao Bo Su; Qing Lin; Qi Zhou
Journal:  Oncoimmunology       Date:  2015-08-24       Impact factor: 8.110

6.  The HIV-1 gp41 ectodomain is cleaved by matriptase to produce a chemotactic peptide that acts through FPR2.

Authors:  Matthew P Wood; Amy L Cole; Colleen R Eade; Li-Mei Chen; Karl X Chai; Alexander M Cole
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

7.  Serum amyloid A induces interleukin-33 expression through an IRF7-dependent pathway.

Authors:  Lei Sun; Ziyan Zhu; Ni Cheng; Qian Yan; Richard D Ye
Journal:  Eur J Immunol       Date:  2014-05-22       Impact factor: 5.532

8.  Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells.

Authors:  Y Wei; R Chen; S Dimicoli; C Bueso-Ramos; D Neuberg; S Pierce; H Wang; H Yang; Y Jia; H Zheng; Z Fang; M Nguyen; I Ganan-Gomez; B Ebert; R Levine; H Kantarjian; G Garcia-Manero
Journal:  Leukemia       Date:  2013-03-29       Impact factor: 11.528

9.  A truncated form of CKbeta8-1 is a potent agonist for human formyl peptide-receptor-like 1 receptor.

Authors:  Aram Elagoz; Duncan Henderson; Poda Suresh Babu; Sylvia Salter; Caroline Grahames; Lorna Bowers; Marie-Odile Roy; Patricia Laplante; Eric Grazzini; Sultan Ahmad; Paola M C Lembo
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

Review 10.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.